This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.The overall objective of this proposal is to demonstrate that HIV-1 protease inhibitors (PI) will adversely affected cardiovascular risk factors due their effects on endothelial function and glucose and lipid metabolism.This exploratory analysis will be done in healthy volunteers so that it is free from the confounding effects of other antiretroviral drugs and from HIV infection itself. The introduction of PI drugs into routine clinical practice has resulted in unprecedented reductions in HIV-related mortality and opportunistic infections, but has been associated with marked abnormalities in glucose and lipid metabolism and alterations in body fat distribution.We will study 10 non obese, non hypertensive, non diabetic, HIV-negative subjects. All will be healthy, between the ages of 20 and 50 years, not pregnant, and not ingesting any drugs. Subjects will be studied on 2 occasions, once before and again at the end of 28-30 days of administration of the PI indinavir. Insulin secretion and whole- body glucose uptake will measured by the hyperglycemic clamp technique. Endothelium dependent and independent blood flow will be evaluated by invasive femoral arterial measurements.The following variables will compare between the baseline and 28-30 day evaluations: Fasting plasma glucose, insulin, c-peptide, whole-body glucose disposal rate, steady-state insulin secretion during hyperglycemia, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, free fatty acids, and changes in LBF in response to the graded drug infusion. Correlations between measures of glucose and lipid metabolism and measures of endothelial function will also be performed.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000750-36
Application #
7717476
Study Section
Special Emphasis Panel (ZRR1-CR-8 (01))
Project Start
2007-12-01
Project End
2008-05-31
Budget Start
2007-12-01
Budget End
2008-05-31
Support Year
36
Fiscal Year
2008
Total Cost
$64,060
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Robinson-Cohen, Cassianne; Bartz, Traci M; Lai, Dongbing et al. (2018) Genetic Variants Associated with Circulating Fibroblast Growth Factor 23. J Am Soc Nephrol 29:2583-2592
Askie, Lisa M; Darlow, Brian A; Finer, Neil et al. (2018) Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. JAMA 319:2190-2201
Srinivasan, Lakshmi; Page, Grier; Kirpalani, Haresh et al. (2017) Genome-wide association study of sepsis in extremely premature infants. Arch Dis Child Fetal Neonatal Ed 102:F439-F445
Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048
Robarge, Jason D; Desta, Zereunesay; Nguyen, Anne T et al. (2017) Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. Breast Cancer Res Treat 161:453-461
Hertz, Daniel L; Speth, Kelly A; Kidwell, Kelley M et al. (2017) Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. Breast Cancer Res Treat 165:659-668
Patel, Yash R; Kirkman, M Sue; Considine, Robert V et al. (2017) Retinopathy predicts progression of fasting plasma glucose: An Early Diabetes Intervention Program (EDIP) analysis. J Diabetes Complications 31:605-610
Robarge, Jason D; Metzger, Ingrid F; Lu, Jessica et al. (2017) Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition. Antimicrob Agents Chemother 61:
Hertz, D L; Kidwell, K M; Seewald, N J et al. (2017) Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer. Pharmacogenomics J 17:521-527
Kadakia, Kunal C; Kidwell, Kelley M; Seewald, Nicholas J et al. (2017) Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. Breast Cancer Res Treat 164:411-419

Showing the most recent 10 out of 767 publications